Literature DB >> 9393589

A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue.

E Shiba1, S J Kim, T Taguchi, M Izukura, T Kobayashi, J Furukawa, E Yayoi, E Shin, Y Takatsuka, H Koyama, S Takai.   

Abstract

Urokinase-type plasminogen activator (u-PA), which cleaves plasminogen to yield plasmin, is a serine protease of fibrinolysis and is presumed to play a key role in extracellular proteolysis and facilitate the migration of cancer cells. This study was conducted prospectively to evaluate the prognostic significance of u-PA antigen level in breast cancer tissues. u-PA concentrations in the cytosol of 226 breast cancer tissues were determined prospectively by enzyme-linked immunosorbent assay using cytosol fractions prepared for steroid hormone assay. The median follow-up period of the patients was 60 months. Various prognostic factors were evaluated by univariate analysis or multivariate analysis using the Cox proportional-hazards method. Patients with primary breast cancer containing high levels of u-PA had a significantly shorter disease-free survival than patients with low levels of u-PA antigens. In multivariate analysis, a high level of u-PA was an independent risk factor for disease-free survival, being independent of age, axillary node status, and estrogen receptor status. Among the major prognostic factors, a high u-PA antigen level, lymph node involvement, and a positive estrogen receptor status were the most important for predicting relapse-free survival (P = 0.044, P < 0.0001, P = 0.0039). This first prospective study confirmed the prognostic significance of the u-PA antigen level in association with other major prognostic factors. The results of our present study suggest that u-PA in breast cancer tissue might be involved in breast cancer invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393589     DOI: 10.1007/s004320050104

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  2 in total

1.  [A 65-year-old female patient with breast cancer accompanied by thrombocytopenia and hyperfibrinolysis].

Authors:  C Aulmann; P Seufert; M Sandherr; G Schlimok; R Schulze; D Oruzio
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

Review 2.  uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.

Authors:  Michael J Duffy; Patricia M McGowan; Nadia Harbeck; Christoph Thomssen; Manfred Schmitt
Journal:  Breast Cancer Res       Date:  2014-08-22       Impact factor: 6.466

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.